

June 29, 2025

To,
The Manager – Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai - 400 001

To,
The Manager – Corporate Compliance Dept.
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, "G"
Block
Bandra - Kurla Complex, Bandra (East),
Mumbai - 400051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Intimation of Board Meeting - pursuant to Regulation 29(1)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that a meeting of the Board of Directors of Kilitch Drugs (India) Limited ("the Company/ KDIL") is scheduled to be held on Wednesday, July 02, 2025, to inter-alia transact the following;

1. To consider and approve the proposal for fund raising by way of issue of equity shares of face value of 10/-each (the "Equity Shares") through Rights Issue.
2. To consider and approve the deployment of the proceeds of the Right Issue.
3. To consider and approve the Draft Letter of Offer for fund raising by way of Right issue and to authorize for Application for in-principal approval for rights issue up to ₹50,00,00,000/- under Regulation 28(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. To consider and transit any other business, if any, which may be placed before the Board with the permission of the Chairman.

This intimation is also being uploaded on the Company's website at: <https://kilitch.com/investor-relations/>



Further, in accordance with the Company's Code of Conduct for Prevention of Insider Trading, the Company has intimated its insiders regarding the closure of the Trading Window. Accordingly, the trading window is closed from June 29, 2025 till the expiry of forty-eight (48) hours from the conclusion of the Board of Directors Meeting.

We request you to kindly take the same on record and acknowledge the receipt.

Yours faithfully,

For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director

